Immunotech Laboratories Stock

Immunotech Laboratories ROA

The Return on Assets (ROA) of Immunotech Laboratories (IMMB) as of Aug 15, 2026 is -9.35 %.

ROA

-9.35 %

Last updated:

In 2026, Immunotech Laboratories's return on assets (ROA) was -9.35 %, a % increase from the - ROA in the previous year.

Access this data via the Eulerpool API

Immunotech Laboratories Stock analysis

What does Immunotech Laboratories do? Immunotech Laboratories Inc is a biotechnology company specializing in the development and marketing of immunotherapies for the treatment of various diseases. The company was founded in 2005 in California, USA. Immunotech Laboratories focuses on the development of immunotherapies for diseases such as HIV/AIDS, Hepatitis C, cancer, and autoimmune diseases. The business model of Immunotech Laboratories is based on the development of innovative immunotherapies using natural compounds. The company collaborates closely with leading scientists and experts in the field of immunology. The developed therapies undergo various clinical trials and are commercially distributed upon successful approval. Immunotech Laboratories specializes in different areas in order to offer a wide range of therapies to its customers. For example, the company develops immunotherapies for the treatment of HIV/AIDS. Immunotech Laboratories combines different compounds to reduce viral load in the body and aid the immune system in fighting the infection. Another important area for Immunotech Laboratories is the development of immunotherapies for cancer treatment. The company utilizes innovative approaches that enable the body's natural defenses to recognize and combat cancer cells. Combination of different compounds is also employed to enhance effectiveness. In addition to these areas, Immunotech Laboratories also offers immunotherapies for the treatment of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. The company employs innovative approaches that enable the immune system to recognize and fight pathogens causing these diseases. Immunotech Laboratories offers a range of products developed based on immunotherapies. These include different combinations of compounds for the treatment of HIV/AIDS and Hepatitis C, as well as immunotherapies for cancer and autoimmune diseases. These products are available in the form of injections, capsules, or tablets and can be prescribed by physicians. Overall, Immunotech Laboratories is an innovative biotechnology company specializing in the development and marketing of immunotherapies. The company collaborates with leading experts in immunology and develops innovative approaches for the treatment of various diseases. The offered products are known for their high effectiveness and tolerability, helping patients worldwide improve their health. Immunotech Laboratories is one of the most popular companies on Eulerpool.

ROA Details

Understanding Immunotech Laboratories's Return on Assets (ROA)

Immunotech Laboratories's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Immunotech Laboratories's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Immunotech Laboratories's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Immunotech Laboratories’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Immunotech Laboratories stock

Return on Assets (ROA) of Immunotech Laboratories is -9.35 % in 2026.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Immunotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Immunotech Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — Immunotech Laboratories

All Key Metrics — Immunotech Laboratories